Tumour necrosis factor-alpha (TNF-alpha) antagonists for acute exacerbations of chronic obstructive pulmonary disease (COPD): a randomised, double-blind, placebo-controlled pilot trial

Ottawa Hospital Research Institute (OHRI) (Canada)0 个研究点目标入组 80 人开始时间: 2010年1月19日最近更新: 2019年3月18日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 80

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23161645 [added 20/02/2019]

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•Both inpatients and outpatients with acute COPD exacerbation will be selected for randomisation. Patients will be considered to fulfill the diagnosis of AECOPD if they meet the following five criteria:
•1. Patients must have had a previous diagnosis of chronic bronchitis, emphysema or COPD established by a physician
•2. Patients must have evidence of airflow obstruction on presentation, defined as a forced expiratory volume in one second (FEV1) equal to or less than 70% of predicted and a FEV1/forced vital capacity (FVC) ratio less 70%
•3. Patients must be greater than 35 years old, either sex
•4. Patients must have a minimum history of 10 pack years smoking
•5. Patients must be experiencing an acute exacerbation of COPD and must meet at least two of the following three clinical criteria for acute COPD exacerbation as defined by Anthonisen:
•5.1. Increased chronic baseline dyspnoea
•5.2. Increased sputum volume
•5.3. Increased sputum purulence
•The above complaints had to have necessitated the emergency department or physician visit.

排除标准

•1. Respiratory failure necessitating admission to an intensive care unit or necessitating use of mechanical invasive or non-invasive (bilevel positive airway pressure [BIPAP]) mechanical ventilation
•2. Physician diagnosed asthma
•3. Any patient who has used oral or injectable corticosteroids during the month preceding trial entry will be excluded, except for patients who have received a single dose of oral or injectable steroids (up to the equivalent of 125 mg of methylprednisolone) in the emergency department prior to randomisation. (Note that standard clinical practice in emergency departments is to treat these patients with oral or intravenous steroids on presentation to the ED. Since it will be functionally impossible to randomise patients prior to initial ED treatment we will allow randomisation of patients who have been given a single dose of steroid in the ED.)
•4. History of chronic lung disease other than COPD. Patients with a history of bronchiectasis, cystic fibrosis, lung cancer and interstitial lung disease.
•5. Pneumonia or congestive heart failure or suspected malignancy on chest x-ray (CXR) prior to randomisation
•6. Patients with a history of infection, or suspected current infection, with mycobacteria tuberculosis, non-tuberculous mycobacteria, or fungal infection
•7. Patients not able to perform an FEV1 assessment
•8. Patients with known adverse reaction or intolerance to systemic steroids or TNF-alpha antagonists
•9. Patients with a history of multiple sclerosis or demyelinating disease (etanercept is contraindicated in these patients)
•10. Inability to provide informed consent or comply with the study protocol due to cognitive impairment, language barrier, or distance greater than 100 kilometres from the study centre
•11. Patients with a history of human immunodeficiency virus (HIV) or other immuno-compromising diseases
•12. Patients with a known malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that was treated with no evidence of recurrence)
•13. Patients who have serum white blood cell (WBC) count less than 3,000 or platelet count less than 100,000 at time of randomisation
•14. Patients who are pregnant or nursing will be excluded. Females of child-bearing age will be required to have a negative serum or urine pregnancy test before randomisation.
•15. Patients with suspected sepsis, i.e., those with temperature greater than 38.5°C or serum WBC greater than 20,000 will be excluded
•16. Patients who have a history or active infection with viral hepatitis B or hepatitis C

研究者

发起方

Ottawa Hospital Research Institute (OHRI) (Canada)

相似试验

已完成

不适用

The safety of anti-tumor necrosis factor-alpha (TNF-a) agents in pregnancy. An observational prospective multicenter study.P04.1Fetus and newborn affected by other maternal medication

DRKS00005036Pharmakoivigilanz- und Beratungszentrum für Embryonaltoxikologie, Charité Berlin625

招募中

不适用

Impact of anti-tumor necrosis factor antibodies treatment on the semen quality of inflammatory bowel diseases patientsfertilityreproduction10013356

NL-OMON33788Erasmus MC, Universitair Medisch Centrum Rotterdam20

进行中（未招募）

不适用

Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patientsFertility influenced by antiTNF treatmentMedDRA version: 9.1Level: LLTClassification code 10016469Term: Fertility investigations

EUCTR2008-005619-16-NLErasmus Medical Center

已完成

不适用

Effect of anti-tumour necrosis factor alpha (TNFa) therapy on blood vessel health in patients with rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritisRheumatoid arthritis

ISRCTN57761809niversity of Dundee (UK)90

招募中

不适用

Severity of Psoriasis and a few inflammatory markers.

CTRI/2022/09/045319VINOLYN DSOUZA